Reply to: "Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy," "Large-Scale DPD Testing Should Be More Than an Option," and "A Big Problem With a Feasible Solution, Not a Small Problem With a Complex Solution".

Bibliographic Details
Title:	Reply to: "Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy," "Large-Scale DPD Testing Should Be More Than an Option," and "A Big Problem With a Feasible Solution, Not a Small Problem With a Complex Solution".
Authors:	Tamraz, Bani, Venook, Alan P.
Source:	JCO Oncology Practice; Feb2025, Vol. 21 Issue 2, p265-266, 2p
Subject Terms:	INBORN errors of metabolism, CANCER chemotherapy, PHARMACOGENOMICS, FLUOROURACIL, GENOTYPES, SINGLE nucleotide polymorphisms, PATIENTS' attitudes
Abstract:	The article focuses on clarifying misunderstandings and responding to critiques of a previous editorial regarding DPYD genotyping and fluoropyrimidine-related toxicities. Topics include the complexity and limitations of current DPYD testing, the rare occurrence of absolute DPYD deficiency, and the importance of patient and clinician choice in testing decisions.
Database:	Complementary Index